近日，北京科净源科技股份有限公司（以下简称"科净源"，301372.SZ）公告披露，其因涉嫌信息披露 违法违规，被中国证监会立案。 作为一家上市不足两年的企业，科净源为何如此快速地陷入监管漩涡？ 科净源方面表示，经自查发现，其全资子公司北京科净源设备安装工程有限公司（以下简称"科净源设 备"）存在对外担保未及时履行审批程序和信息披露义务的情形。"公司在发现上述对外担保事项后第一 时间成立专项核查小组，根据调查结果，对相关责任人员进行处罚，责令相关人员吸取教训、总结经 验。" 上海汉联律师事务所宋一欣律师向《中国经营报》记者表示，如果上述担保没有及时公开披露，涉嫌信 息披露违法违规，证监会将会按照证券法对其作出行政处罚。 信披违规 2023年8月11日，科净源顶着"水环境治理领军企业"的光环成功登陆深交所创业板，发行价45元/股，募 集资金7.71亿元。 上市当年，科净源的业绩便出现"断崖式"下滑。2023年公司营收同比下跌31.3%至3.02亿元，归母净利 润仅1940万元，同比骤降77.53%。 进入2024年，情况并未好转，反而进一步恶化。据2024年度业绩预告，科净源预计全年归母净利润亏损 9934万元 ...

基于上述违规行为，依据《上市公司信息披露管理办法》（证监会令第182号）第五十二条规定，浙江 证监局决定对浙江富润及相关责任人员分别采取出具警示函的监督管理措施，并记入证券期货市场诚信 档案。 公开资料显示，浙江富润成立于1994 年5月，主要经营业务包括：交通基础设施及热电工程的投资开 发，旅游服务，针纺织品、服装的制造加工等。 公告显示， 2025年1月25日，浙江富润披露《2024年度业绩预亏公告》，预计2024年度营业收入约为 3.16亿元，扣除与主营业务无关的业务收入和不具备商业实质的收入后的营业收入约为3.06亿元。3月19 日，公司披露《2024年度业绩预告更正及致歉公告》，更正后预计实现营业收入约为3.06亿元，扣除与 主营业务无关的业务收入和不具备商业实质的收入后的营业收入约为2.87亿元，低于3亿元。公司业绩 预告相关信息披露不准确。 公司上述行为违反了《上市公司信息披露管理办法》（证监会令第182号）第三条规定。 公司董事长陈黎伟、总经理车柯、财务总监汪涛、董事会秘书叶立群未能勤勉尽责，违反了《上市公司 信息披露管理办法》（证监会令第182号）第四条、第五十一条规定，对上述违规行为负有主 ...

文/梧桐小编 近日，深圳中青宝互动网络股份有限公司（300052）公告公司及相关当事人收到深圳证监局《行政处罚决定书》。经查明，中青宝存在以下违法事实：1、2019 年 至 2021 年年度报告存在虚假记载。2、未及时披露实际控制人被采取刑事强制措施。2023 年 12 月 29 日，中青宝实际控制人张云霞因涉嫌拒不执行判决、裁定罪被 公安机关刑事拘留，并于当日被采取取保候审的刑事强制措施，中青宝及其实际控制人李瑞杰不晚于 2024 年 4 月 19 日知悉张云霞被采取刑事强制措施。依据《证 券法》的规定，中青宝应当及时披露上述事项，但张云霞、李瑞杰为避免影响中青宝及其关联公司融资等，共同要求中青宝暂不披露。至 2024 年 7 月 26 日，中青 宝才发布《关于实际控制人被采取强制措施并收到〈取保候审决定书〉、〈不起诉决定书〉及〈解除取保候审决定书〉的公告》对上述事项予以披露。深圳证监局 决定对中青宝罚款500万元，对实控人张云霞、李瑞杰合计罚款550万元，对时任中青宝子公司深圳市宝腾互联科技有限公司时任总经理张超罚款200万元。对时任 总经理李逸伦罚款150万元，对时任财务总监罚款50万元，对时任董秘高国 ...

Core Viewpoint - Chongqing Securities Regulatory Bureau has taken corrective measures against Chongqing Enjie Numi Technology Co., Ltd. (Numi Technology) due to violations related to disclosure and compliance issues [1][4]. Group 1: Regulatory Actions - Numi Technology has been ordered to correct its practices and has received a warning letter from the regulatory authority [1][4]. - Key executives, including Lu Donghua, Wang Xingguang, Zhou Xianghuai, Li Xiaohua, and Li Ningli, have been subjected to regulatory talks and received warning letters [1][4]. Group 2: Violations Identified - The company failed to timely disclose the progress of commitments made regarding competition issues after Shanghai Enjie New Materials Technology Co., Ltd. acquired a 76.36% stake in Numi Technology [2][3]. - There were incomplete disclosures regarding related party transactions, specifically labor services provided to Shanghai Enjie New Materials Technology Co., Ltd. from 2022 to 2023, which did not follow the required approval procedures [3][4]. - Key executives are held primarily responsible for these violations, indicating a lack of diligence in their duties [3][4].

4月1日晚间，塞力医疗连发三条公告。因未按期归还暂时补流的募集资金，塞力医疗被上海证交所通报 批评并被湖北证监局责令改正；因未按规定披露关联交易及大股东资金占用情况，未按规定披露重要合 同订立事项，塞力医疗遭湖北证监局行政处罚。 累计未归还募集资金4.68亿元 经查，塞力医疗于2024年7月27日前未按期归还暂时补流的募集资金8200万元，于2024年8月29日前未按 期归还暂时补流的募集资金3.74亿元，于2025年1月8日前未按期归还暂时补流的募集资金5000万元，并 导致2023年7月27日、2023年8月29日和2024年1月8日披露的信息"使用期限不超过12个月"与实际不符。 根据相关公告，塞力医疗于2024年12月30日归还800万元至募集资金专用账户，于2025年2月27日归还 3000万元至募集资金专用账户。截至2025年2月28日，塞力医疗累计未归还募集资金合计为4.68亿元。 上海证交所认为，塞力医疗将多笔闲置募集资金用于暂时补充流动资金，均未在规定期限内及时归还， 且所涉金额较大，上述行为违反了相关规定；时任董事长温伟作为公司主要负责人，时任总经理王政作 为公司日常经营管理的具体负责人， ...

塞力斯医疗科技集团股份有限公司 关于收到中国证券监督管理委员会湖北监管局 《行政处罚事先告知书》的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担个别及连带责任。 登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：603716 证券简称：塞力医疗 公告编号：2025-026 债券代码：113601 债券简称：塞力转债 塞力斯医疗科技集团股份有限公司（以下简称"公司"）于2024年3月25日收到中国证券监督管理委员会 （以下简称"中国证监会"）下发的《立案告知书》（编号：证监立案字0052024002号）。因公司涉嫌信 息披露违法违规，根据《中华人民共和国证券法》《中华人民共和国行政处罚法》等法律法规，中国证 监会决定对公司立案。具体内容详见公司于2024年3月26日在上海证券交易所网站发布的《关于收到中 国证券监督管理委员会立案告知书的公告》（公告编号2024-022）。 公司于2025年4月1日收到中国证监会湖北监管局下发的《行政处罚事先告知书》（编号：鄂处罚字 [2025]1号）。现就相关情况公告如下： 一、《行政处罚 ...

| 处分， 交易所1年内不接受国宏工具提交的上市申请； | | --- | | 对IPO项目保荐机构申万宏源及两名保代予以纪律处分， 交易所6个月内不接受两名保代签字的发行上市申请文件及信息披露文件； | | 对IPO项目申报会计师公证天业及两名签字注册会计师予以纪律处分， 交易所6个月内不接受两名会计师签字的发行上市申请文件及信息披露文件； | | 对IPO项目申报律师上海通力及三名签字律师予以纪律处分。 | | 据查明，该公司在首次公开发行股票申请过程中，未准确披露研发人员数量及研发投入金额，累计多计研发投入 727.84 万元；未经审议决策程序代控股股东对外履 | | 延展阅读： 《又一科创板IPO终止！曾被抽中现场检查，两科创指标踩线达标，是否有水份？》 | | 行对赌回购义务，未充分披露公司治理存在的缺陷；未准确披露实际控制人的一致行动人；未充分计提应收账款坏账准备。 | 关于对国宏工具系统（无锡）股份有限公司及相关责任人予以纪律处分的决定 当事人： 国宏工具系统（无锡）股份有限公司； 吴健新，国宏工具系统（无锡）股份有限公司时任董事长； 吕显豹，国宏工具系统（无锡）股份有限公司时任总经理； 姜雨康 ...

Core Viewpoint - The Shenzhen Stock Exchange issued a regulatory letter to Zhongshan United Optoelectronics Technology Co., Ltd. for inaccurate and untimely information disclosure regarding its "heavy-duty quadruped robot" business, raising concerns about the company's governance and financial health [2] Financial Performance - In the first half of 2024, the company's revenue reached 848 million yuan, a year-on-year increase of 5.75%, but net profit declined by 27.67% to 28.25 million yuan, with a non-recurring net profit drop of 33.32% [3] - The decline in profitability is attributed to a significant increase in R&D expenses, which rose by 34.28% to 104 million yuan, and intensified competition in the consumer electronics market affecting gross margins [3] - The company's operating cash flow turned negative, with a net outflow of 53.81 million yuan, a decrease of 61 million yuan year-on-year, and free cash flow worsened to -37.30 million yuan, indicating increased pressure on the cash flow [3] Financial Health - As of the end of Q3 2024, the company's debt-to-asset ratio rose to 42.43%, an increase of 6.67 percentage points compared to the same period in 2023, with long-term borrowings increasing by 48.84% [4] - Interest-bearing debt ratio increased to 17.64%, while inventory value reached 441 million yuan, accounting for 27.23% of net assets, a 20.29% increase from the end of the previous year [4] - If market demand does not meet expectations, liquidity risks may further escalate [4] Business Performance - The company maintains strong competitiveness in traditional sectors such as security monitoring and intelligent driving, with high-end lens products dominating the security market and improving production capacity in vehicle-mounted lenses [5] - However, the failure of the robot project highlights deficiencies in the company's technological reserves and commercialization capabilities in emerging fields, with high R&D investments not translating into actual revenue [5] Future Outlook - The Shenzhen Stock Exchange has mandated the company’s board to immediately rectify and enhance compliance in information disclosure [5] - The company plans to release its 2024 annual report on April 21, 2025, with market focus on debt structure optimization, cash flow improvement, and adjustments in emerging businesses [5] - In the short term, the company needs to restore investor confidence, while long-term sustainability will depend on balancing innovation investments with profitability in its optical core business [5]

Core Viewpoint - Zhejiang Tailin Biotechnology Co., Ltd. received a warning letter from the Zhejiang Securities Regulatory Bureau due to information disclosure violations, raising concerns about the company's operational compliance and financial stability [1][2]. Group 1: Information Disclosure Violations - The Zhejiang Securities Regulatory Bureau found that Tailin Biotechnology failed to disclose issues related to insufficient production capacity of fundraising projects, land use changes, and investment pauses in joint ventures [2]. - The company and its responsible personnel, including the chairman and CFO, were held accountable for these violations, which contravened the regulations on timely and accurate information disclosure [2][3]. - Tailin Biotechnology acknowledged the issues raised in the warning letter and committed to improving compliance and information disclosure practices [3]. Group 2: Previous Regulatory Issues - This warning letter is not the first regulatory issue for Tailin Biotechnology; the company faced fines for violations of fire safety and environmental regulations in the past [4]. - The incidents highlight the importance of adhering to legal and regulatory requirements, especially in the context of ongoing reforms in the registration system [4]. Group 3: Financial Performance - Tailin Biotechnology's financial performance has shown signs of decline, with revenues of 374 million yuan, 270 million yuan, and 242 million yuan for 2022, 2023, and the first three quarters of 2024, respectively, reflecting year-on-year changes of 32.00%, -27.82%, and 19.37% [5]. - The net profit attributable to shareholders also decreased significantly, with figures of 80 million yuan, 20 million yuan, and 11 million yuan for the same periods, showing year-on-year changes of 25.43%, -75.32%, and -46.91% [5]. - The company has been exploring the cell therapy equipment sector but announced a delay in the project timeline for the "Cell Therapy Industrialization Equipment Manufacturing Base Project" due to changes in implementation methods and macroeconomic factors [5].